Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $16.00.

Several equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, March 23rd. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research report on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Monday, April 20th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th.

Coya Therapeutics Price Performance

COYA stock opened at $4.29 on Wednesday. The stock has a market cap of $100.64 million, a price-to-earnings ratio of -3.38 and a beta of 0.55. The company has a 50 day simple moving average of $4.37 and a 200 day simple moving average of $5.06. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The firm had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. On average, equities research analysts anticipate that Coya Therapeutics will post -1.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds have recently made changes to their positions in COYA. Alyeska Investment Group L.P. bought a new position in Coya Therapeutics during the 4th quarter worth approximately $4,640,000. AWM Investment Company Inc. acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at about $4,205,000. CM Management LLC boosted its position in shares of Coya Therapeutics by 16.7% during the 4th quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after purchasing an additional 50,000 shares in the last quarter. Private Management Group Inc. acquired a new stake in Coya Therapeutics during the fourth quarter worth approximately $1,626,000. Finally, Marshall Wace LLP grew its position in shares of Coya Therapeutics by 438.8% during the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after buying an additional 183,533 shares during the period. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.